132 related articles for article (PubMed ID: 23216087)
1. Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on motor and cognitive functions in a rat model of Parkinson's disease.
Razavinasab M; Shamsizadeh A; Shabani M; Nazeri M; Allahtavakoli M; Asadi-Shekaari M; Esmaeli-Mahani S; Sheibani V
Fundam Clin Pharmacol; 2013 Dec; 27(6):632-40. PubMed ID: 23216087
[TBL] [Abstract][Full Text] [Related]
2. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
3. The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson's disease.
Hadadianpour Z; Fatehi F; Ayoobi F; Kaeidi A; Shamsizadeh A; Fatemi I
Neurol Res; 2017 Sep; 39(9):845-851. PubMed ID: 28701075
[TBL] [Abstract][Full Text] [Related]
4. Sensation of TRPV1 via 5-hydroxytryptamine signaling modulates pain hypersensitivity in a 6-hydroxydopamine induced mice model of Parkinson's disease.
Li M; Zhu M; Xu Q; Ding F; Tian Y; Zhang M
Biochem Biophys Res Commun; 2020 Jan; 521(4):868-873. PubMed ID: 31708101
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of transient receptor potential vanilloid-1 confers neuroprotection, reduces tumor necrosis factor-alpha, and increases IL-10 in a rat stroke model.
Hakimizadeh E; Shamsizadeh A; Roohbakhsh A; Arababadi MK; Hajizadeh MR; Shariati M; Rahmani MR; Allahtavakoli M
Fundam Clin Pharmacol; 2017 Aug; 31(4):420-428. PubMed ID: 28199737
[TBL] [Abstract][Full Text] [Related]
6. Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.
Kopalli SR; Noh SJ; Koppula S; Suh YH
Neurotoxicology; 2013 Jan; 34():25-32. PubMed ID: 23068419
[TBL] [Abstract][Full Text] [Related]
7. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.
Gavva NR; Tamir R; Qu Y; Klionsky L; Zhang TJ; Immke D; Wang J; Zhu D; Vanderah TW; Porreca F; Doherty EM; Norman MH; Wild KD; Bannon AW; Louis JC; Treanor JJ
J Pharmacol Exp Ther; 2005 Apr; 313(1):474-84. PubMed ID: 15615864
[TBL] [Abstract][Full Text] [Related]
8. The effect of intra-ventral hippocampus administration of TRPV1 agonist and antagonist on spatial learning and memory in male rats.
Amiresmaili S; Shamsizadeh A; Allahtavakoli M; Pourshanazari AA; Roohbakhsh A
Pharmacol Rep; 2014 Feb; 66(1):10-4. PubMed ID: 24905300
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
10. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Laloux C; Petrault M; Lecointe C; Devos D; Bordet R
Pharmacol Res; 2012 May; 65(5):514-22. PubMed ID: 22391246
[TBL] [Abstract][Full Text] [Related]
11. The C-terminal domain of the heavy chain of tetanus toxin given by intramuscular injection causes neuroprotection and improves the motor behavior in rats treated with 6-hydroxydopamine.
Mendieta L; Bautista E; Sánchez A; Guevara J; Herrando-Grabulosa M; Moran J; Martínez R; Aguilera J; Limón ID
Neurosci Res; 2012 Oct; 74(2):156-67. PubMed ID: 22967672
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F
Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206
[TBL] [Abstract][Full Text] [Related]
14. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
[TBL] [Abstract][Full Text] [Related]
15. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model.
Fatemi I; Abdollahi A; Shamsizadeh A; Allahtavakoli M; Roohbakhsh A
Acta Neuropsychiatr; 2021 Feb; 33(1):15-21. PubMed ID: 32967746
[TBL] [Abstract][Full Text] [Related]
16. SK channel blockade reverses cognitive and motor deficits induced by nigrostriatal dopamine lesions in rats.
Chen L; Deltheil T; Turle-Lorenzo N; Liberge M; Rosier C; Watabe I; Sreng L; Amalric M; Mourre C
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1295-306. PubMed ID: 24661728
[TBL] [Abstract][Full Text] [Related]
17. Cerium oxide nanoparticles could ameliorate behavioral and neurochemical impairments in 6-hydroxydopamine induced Parkinson's disease in rats.
Hegazy MA; Maklad HM; Samy DM; Abdelmonsif DA; El Sabaa BM; Elnozahy FY
Neurochem Int; 2017 Sep; 108():361-371. PubMed ID: 28527632
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective Effects of Sulphated Agaran from Marine Alga Gracilaria cornea in Rat 6-Hydroxydopamine Parkinson's Disease Model: Behavioural, Neurochemical and Transcriptional Alterations.
Souza RB; Frota AF; Sousa RS; Cezario NA; Santos TB; Souza LM; Coura CO; Monteiro VS; Cristino Filho G; Vasconcelos SM; da Cunha RM; Aguiar LM; Benevides NM
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):159-170. PubMed ID: 27612165
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Kumar A; Sharma N; Gupta A; Kalonia H; Mishra J
Brain Res; 2012 Aug; 1471():13-22. PubMed ID: 22789904
[TBL] [Abstract][Full Text] [Related]
20. The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis.
Carmo MR; Menezes AP; Nunes AC; Pliássova A; Rolo AP; Palmeira CM; Cunha RA; Canas PM; Andrade GM
Neuropharmacology; 2014 Jun; 81():142-52. PubMed ID: 24508709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
